Kelly Financial Services LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,517 shares of the medical research company's stock, valued at approximately $3,784,000. Amgen accounts for about 1.1% of Kelly Financial Services LLC's portfolio, making the stock its 27th biggest position.
Other institutional investors have also recently made changes to their positions in the company. Capital Performance Advisors LLP bought a new position in Amgen in the 3rd quarter valued at $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen during the third quarter valued at $29,000. Hershey Financial Advisers LLC bought a new position in shares of Amgen in the second quarter worth about $30,000. Matrix Trust Co purchased a new position in Amgen in the 3rd quarter worth about $36,000. Finally, Livelsberger Financial Advisory bought a new stake in Amgen during the 3rd quarter valued at about $56,000. Institutional investors own 76.50% of the company's stock.
Amgen Stock Performance
Shares of Amgen stock traded up $2.68 during midday trading on Friday, hitting $272.11. The company had a trading volume of 3,244,015 shares, compared to its average volume of 3,140,853. The stock has a market cap of $146.27 billion, a price-to-earnings ratio of 34.84, a PEG ratio of 2.68 and a beta of 0.56. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The company has a fifty day simple moving average of $273.95 and a 200 day simple moving average of $307.20.
Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business's revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.96 earnings per share. As a group, analysts predict that Amgen Inc. will post 19.57 earnings per share for the current fiscal year.
Amgen Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is a positive change from Amgen's previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.50%. Amgen's dividend payout ratio is currently 115.24%.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on AMGN shares. StockNews.com lowered shares of Amgen from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Jefferies Financial Group restated a "buy" rating and set a $380.00 price objective on shares of Amgen in a report on Tuesday, November 12th. Truist Financial decreased their target price on Amgen from $333.00 to $298.00 and set a "hold" rating for the company in a research report on Wednesday, January 8th. Wolfe Research initiated coverage on Amgen in a research report on Friday, November 15th. They set a "peer perform" rating on the stock. Finally, UBS Group decreased their price objective on Amgen from $335.00 to $326.00 and set a "neutral" rating for the company in a report on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $314.91.
Check Out Our Latest Research Report on AMGN
Amgen Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Stories
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
